Furthermore, a subcutaneous tumorigenesis mouse model showed that IGF2BP3 KD inhibited in vivo xenograft tumor growth and mass of OE-19 cells (Fig. 2G-I), suggesting that IGF2BP3 KD can suppress tumor progression in AEG cancer. This evidence concerns the gene IGF2BP3 and neoplasm.